⌘K (Command K) to search

Sign in Sign up free

Insider · CIK 0002017374

Lees-Rolfe Garth

Reports to the SEC for 2 companies · LEXINGTON, MA

Transactions

8

Companies

2

Filings

3

CIK

0002017374

Forms 4 and 5

Insider transactions

8 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−5,834 sh	—	—	0
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+5,834 sh	—	—	5,834
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−90K sh	—	—	0
2025-01-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+90K sh	—	—	90,000
2025-01-03	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+471K sh	—	—	470,861
2025-01-03	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+235K sh	—	—	235,383
2025-01-03	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+433K sh	—	—	432,853
2024-04-01	IKTInhibikase Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+90K sh	—	—	90,000

Recent filings

3

Accepted (ET)
Jan 224
Lees-Rolfe Garth0000950170-25-007746
SEC(opens sec.gov)
Jan 74
Lees-Rolfe Garth0000950170-25-003130
SEC(opens sec.gov)
Apr 24
Lees-Rolfe Garth0000950170-24-040358
SEC(opens sec.gov)

Companies

2

Address

1 CRANBERRY HILL, SUITE 200

LEXINGTON, MA, 02421